You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 5,240,694


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 5,240,694
Title: Combined antiviral and antimediator treatment of common colds
Abstract:The common cold is best treated by providing a combination of antiviral agents and antiinflammatory compounds to a patient infected with a cold virus. An antiviral agent and two antiinflammatory compounds given to a person infected with a cold virus simultaneously reduces the likelihood of a cold developing and the amount and duration of viral shedding, as well as substantially reduces the severity of individual cold symptoms and the overall number and severity of cold symptoms. Supplementing the activity of the combined antiviral and antiinflammatory agents with such compounds as antihistamines and alpha agonists results in suprisingly good nasal benefits. The combination therapy, termed COVAM therapy, is well tolerated and has no evidence of short-term toxicity.
Inventor(s): Gwaltney, Jr.; Jack M. (Free Union, VA)
Assignee: University of Virginia (Charlottesville, VA) Center for Innovative Technology (Herndon, VA)
Application Number:07/794,520
Patent Claims:1. A method of treating the common cold, comprising the steps of:

administering to a patient in need thereof a therapeutically effective amount of at least one antiviral agent specific for a virus which causes the common cold selected from the group consisting of rhinoviruses, adenoviruses, enteroviruses, coronaviruses, respiratory synctial viruses, influenza viruses and parainfluenza viruses; and

administering to said patient a therapeutically effective amount of at least one antiinflammatory compound specific for inflammatory pathways of the common cold selected from the group consisting of the parasympathetic pathway, the cyclooxygenase and lipoxygenase pathway, the histamine pathway, the alpha adrenergic pathway, the interleukin-1 pathway, the kinin pathway, and the pathway used by exogenous opioid agonists, said steps of administering said antiviral agent and said antiinflammatory compound being performed at approximately the same time and achieving a synergistic result in the treatment of the common cold.

2. A method as recited in claim 1 wherein said antinflammatory compound is selected from the group consisting of ipratropium, atropine methonitrate, exogenous opioid agonists, alpha adrenergic agonists, chlorpheniramine, prostaglandin blockers and antagonists, leukotriene blockers and antagonists, parasympathetic blockers and antagonists, interleukin blockers and antagonists, naproxen and ibuprophen.

3. A method as recited in claim 1 wherein said antiviral agent is selected from the group consisting of integerons, interferon inducers, capsid binding agents, benzoimidazoles, 1'-methyl spiro(adamantane-2,3-pyrrolidine)maleate, isatin thiosemicarbazone, fusidic acid, substituted trizainoindoles, 2,6-diphenyl-3-methyl-2,3-dihydroimidazo[2,1-b]thiazole, 3-alpha-naphthl-5-diethylcarbamoyl-1,2,4-oxadiazole, oxolinic acid, isoquinolines, 1-p-chlorophenyl-3-(m-3-isobutylguanidinophenyl)urea hydrochloride, anti ICAM-1 antibody synthetic ICAM-1, amantadine, rimantadine, and ribavirin.

4. A method as recited in claim 1 further comprising the step of administering to said patient a therapeutically effective amount of at least one antihistamine compound which is different from said antiinflammatory compound.

5. A method as recited in claim 4 wherein said antihistamine compound is selected from the group consisting of chlorpheniramine, diphenylhydramine, brompheniramine, clemastine, and terfenadine.

6. A method as recited in claim 1 further comprising the step of administering to said patient a therapeutically effective amount of at least one alpha agonist compound which is different from said antiinflammatory compound.

7. A method as recited in claim 6 wherein said alpha agonist is selected from the group consisting of phenylephrine, pseudoephedrine, phenylpropanolamine, oxymetazoline, and xylometazoline.

8. A method of treating the common cold, comprising the steps of:

administering to a patient in need thereof a therapeutically effective amount of at least one antiviral agent specific for a virus which causes the common cold selected from the group consisting of rhinoviruses, adenoviruses, enteroviruses, coronaviruses, respiratory syncytial viruses, influenza viruses and parainfluenza viruses; and

administering to said patient a therapeutically effective amount of at least two antiinflammatory compounds specific for at least two different inflammatory pathways of the common cold selected from the group consisting of the parasympathetic pathway, the cyclooxygenase and lipoxygenase pathway, the histamine pathway, the alpha adrenergic pathway, the interleukin-1 pathway, the kinin pathway, and the pathway used by exogenous opioid agonists, said steps of administering said antiviral agent and said two antiinflammatory compounds being performed at approximately the same time and achieving a synergistic result in the treatment of the common cold.

9. A method as recited in claim 8 wherein said antiviral agent is interferon .alpha.2, and wherein said antiinflammatory agents naproxen and ipratropium.

10. A method as recited in claim 8 wherein at least one of said antiviral agent and said antiinflammatory compounds is administered orally and at least one of said antiviral agent and said antiinflammatory compounds is administered nasally.

11. A method as recited in claim 8 wherein said antiviral agent and said antiinflammatory agents are administered simultaneously using a metered dose inhaler.

Details for Patent 5,240,694

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Jubilant Hollisterstier Llc N/A positive skin test control-histamine Injection 103891 03/13/1924 ⤷  Try a Trial 2039-02-26
Hoffmann-la Roche Inc. PEGASYS COPEGUS COMBINATION PACK peginterferon alfa-2a and ribavirin 125083 06/04/2004 ⤷  Try a Trial 2039-02-26
Schering Corporation A Subsidiary Of Merck & Co., Inc. PEGINTRON/ REBETOL COMBO PACK peginterferon alfa-2b and ribavirin 125196 06/13/2008 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.